XNAS · CCCC
+2.63% · +$0.1100 · Vol 2.5M
Market closed · last close 4:00 PM ET · price as of 19:51:40 ET
C4 Therapeutics, Inc.

C4 Therapeutics, Inc.

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
$4.30
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is CCCC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for CCCC are being assembled.
About C4 Therapeutics, Inc.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2020
Employees
104
Country
US

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.19
Day high
$4.40
Day low
$4.13
Previous close
$4.19
52W high
$4.64
-7.38% from high
52W low
$3.79
60% of range
Market cap
$463.3M
EPS
$-1.3800
Shares out
110.6M
Volume
2.5M
VWAP
$4.27
Price history computed in-house
1W
+2.75%
1M
+12.71%
SMA 50 $4.15 · above
SMA 200 $4.15 · above
52W position 60%
Veridion warehouse edge

Warehouse intelligence for CCCC.

Veridion Score
57
0: 581: 392: 773: 204: 815: Not reported
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

CCCC insider activity

C4 Therapeutics, Inc.

Score
Coverage building
Pressure
Mixed
Filings
0
Buys / sells
0 / 0
Net value
Not disclosed
Insiders
0
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Mixed: Not disclosed across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Coverage building

The current Form 4 feed did not return value-bearing open-market rows for CCCC.

Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

CCCC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for CCCC in this window.
Lobbying spend

CCCC lobbying filings, year to date.

Registered lobbying filings matched to C4 Therapeutics, Inc..

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for CCCC in this window.
Latest news · CCCC
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for CCCC.
Options
Sovereign unlock shows live options positioning for CCCC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.